EP Patent

EP1752536A1 — Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same

Assigned to Alphagen Co Ltd · Expires 2007-02-14 · 19y expired

What this patent protects

The present invention provides a polynucleotide that not only has a high RNA interference effect on its target gene, but also has a very small risk of causing RNA interference against a gene unrelated to the target gene. A sequence segment conforming to the following rules (a) to…

USPTO Abstract

The present invention provides a polynucleotide that not only has a high RNA interference effect on its target gene, but also has a very small risk of causing RNA interference against a gene unrelated to the target gene. A sequence segment conforming to the following rules (a) to (d) is searched from the base sequences of a target gene for RNA interference and, based on the search results, a polynucleotide capable of causing RNAi is designed, synthesized, etc.: (a) The 3' end base is adenine, thymine, or uracil, (b) The 5' end base is guanine or cytosine, (c) A 7-base sequence from the 3' end is rich in one or more types of bases selected from the group consisting of adenine, thymine, and uracil, and (d) The number of bases is within a range that allows RNA interference to occur without causing cytotoxicity.

Drugs covered by this patent

Patent Metadata

Patent number
EP1752536A1
Jurisdiction
EP
Classification
Expires
2007-02-14
Drug substance claim
No
Drug product claim
No
Assignee
Alphagen Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.